Research programme: bacterial biofilm therapies - Caliper Life Sciences/Morphochem

Drug Profile

Research programme: bacterial biofilm therapies - Caliper Life Sciences/Morphochem

Latest Information Update: 07 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Caliper Life Sciences; Morphochem AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 07 Feb 2017 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 09 Aug 2006 Xenogen Corporation has been acquired and merged into Caliper Life Sciences
  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top